X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Precision exercised its option to regain rights for the programs, including its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Prevail Therapeutics
Deal Size: $555.0 million Upfront Cash: $100.0 million
Deal Type: Termination April 16, 2024
Details:
ECUR-506, incorporates an ARCUS nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a donor vector that inserts the desired functional OTC gene for the treatment of Ornithine Transcarbamylase deficiency in infants.
Lead Product(s): ECUR-506
Therapeutic Area: Genetic Disease Product Name: ECUR-506
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
The net proceeds will be used in the clinical development of PBGENE-HBV, designed to both eliminate cccDNA and inactivate HBV DNA. It is being evaluated for the treatment of Chronic Hepatitis B.
Lead Product(s): PBGENE-HBV
Therapeutic Area: Infections and Infectious Diseases Product Name: PBGENE-HBV
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Guggenheim Securities, LLC
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 01, 2024
Details:
The net proceeds will be used in the clinical development of PBGENE-HBV, designed to both eliminate cccDNA and inactivate HBV DNA. It is being evaluated for the treatment of Chronic Hepatitis B.
Lead Product(s): PBGENE-HBV
Therapeutic Area: Infections and Infectious Diseases Product Name: PBGENE-HBV
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Guggenheim Securities, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
PBGENE-HBV first and only potentially curative gene editing program that acts as a cccDNA/HBV DNA inhibitor. It is being developed for the treatment of chronic hepatitis B.
Lead Product(s): PBGENE-HBV
Therapeutic Area: Infections and Infectious Diseases Product Name: PBGENE-HBV
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Under the agreement, TG Therapeutics received exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
Lead Product(s): Azercabtagene Zapreleucel
Therapeutic Area: Immunology Product Name: Azer-cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TG Therapeutics
Deal Size: $305.5 million Upfront Cash: $17.5 million
Deal Type: Licensing Agreement February 12, 2024
Details:
Under the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
Lead Product(s): Azercabtagene Zapreleucel
Therapeutic Area: Immunology Product Name: Azer-cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TG Therapeutics
Deal Size: $315.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement January 09, 2024
Details:
Arcus is a platform designed to develop in vivo gene editing therapies, including gene insertion, excision, and elimination. It has received TGA approval for initiation of Phase 1/2 trial evaluating ECUR-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency.
Lead Product(s): ECUR-506
Therapeutic Area: Genetic Disease Product Name: ECUR-506
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: iECURE
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma and has an option to develop up to three other cancer research programs.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Imugene
Deal Size: $662.0 million Upfront Cash: $29.0 million
Deal Type: Licensing Agreement August 15, 2023
Details:
PBCAR0191 (azercabtagene zapreleucel) is an investigational anti-CD19 allogeneic CAR T candidate being evaluated in a Phase 1/2a clinical trial of adult subjects with relapsed or refractory (R/R) non-Hodgkin lymphoma.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
